EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Volume 208 / Numéro 3 (2014) Biologie Aujourd'hui, 208 3 (2014) 211-216 Références
Accès gratuit
Numéro
Biologie Aujourd'hui
Volume 208, Numéro 3, 2014
Page(s) 211 - 216
Section Régulation de la pression artérielle
DOI https://doi.org/10.1051/jbio/2014012
Publié en ligne 5 décembre 2014
  • Azizi M., Steichen O., Frank M., Bobrie G., Plouin P.F., Sapoval M., Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertension. Eur J Vasc Endovasc Surg, 2012, 43, 293–299. [CrossRef] [PubMed] [Google Scholar]
  • Bakris G.L., Nadim M.K., Haller H., Lovett E.G., Schafer J.E., Bisognano J.D., Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens, 2012, 6, 152–158. [CrossRef] [PubMed] [Google Scholar]
  • Bisognano J.D., Bakris G., Nadim M.K., Sanchez L., Kroon A.A., Schafer J., de Leeuw P.W., Sica D.A., Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol, 2011, 58, 765–773. [CrossRef] [PubMed] [Google Scholar]
  • Brandt M.C., Mahfoud F., Reda S., Schirmer S.H., Erdmann E., Bohm M., Hoppe U.C., Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol, 2012a, 59, 901–909. [CrossRef] [PubMed] [Google Scholar]
  • Brandt M.C., Reda S., Mahfoud F., Lenski M., Bohm M., Hoppe U.C., Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol, 2012b, 60, 1956–1965. [CrossRef] [PubMed] [Google Scholar]
  • Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D., White A., Cushman W.C., White W., Sica D., Ferdinand K., Giles T.D., Falkner B., Carey R.M., Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension, 2008, 51, 1403–1419. [CrossRef] [PubMed] [Google Scholar]
  • Cuspidi C., Macca G., Sampieri L., Michev I., Salerno M., Fusi V., Severgnini B., Meani S., Magrini F., Zanchetti A., High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens, 2001, 19, 2063–2070. [CrossRef] [PubMed] [Google Scholar]
  • Daugherty S.L., Powers J.D., Magid D.J., Tavel H.M., Masoudi F.A., Margolis K.L., O’Connor P.J., Selby J.V., Ho P.M., Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation, 2012, 125, 1635–1642. [CrossRef] [PubMed] [Google Scholar]
  • Davis M.I., Filion K.B., Zhang D., Eisenberg M.J., Afilalo J., Schiffrin E.L., Joyal D., Effectiveness of Renal Denervation Therapy for Resistant Hypertension: A Systematic Review and Meta-Analysis. J Am Coll Cardiol, 2013, 62, 231–241. [CrossRef] [PubMed] [Google Scholar]
  • de la Sierra A., Segura J., Banegas J.R., Gorostidi M., de la Cruz J.J., Armario P., Oliveras A., Ruilope L.M., Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension, 2011, 57, 898–902. [CrossRef] [PubMed] [Google Scholar]
  • DiBona G.F., Esler M., Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol, 2010, 298, R245–R253. [CrossRef] [PubMed] [Google Scholar]
  • Dorr O., Liebetrau C., Mollmann H., Achenbach S., Sedding D., Szardien S., Willmer M., Rixe J., Troidl C., Elsasser A., Hamm C., Nef H.M., Renal sympathetic denervation does not aggravate functional or structural renal damage. J Am Coll Cardiol, 2013, 61, 479–480. [CrossRef] [PubMed] [Google Scholar]
  • Doumas M., Douma S., Renal sympathetic denervation: the jury is still out. Lancet, 2010, 376, 1878–1880. [CrossRef] [PubMed] [Google Scholar]
  • Esler M.D., Krum H., Sobotka P.A., Schlaich M.P., Schmieder R.E., Bohm M., Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet, 2010, 376, 1903–1909. [CrossRef] [PubMed] [Google Scholar]
  • Esler M.D., Krum H., Schlaich M., Schmieder R.E., Bohm M., Sobotka P.A., Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation, 2012, 126, 2976–2982. [CrossRef] [PubMed] [Google Scholar]
  • Hering D., Lambert E.A., Marusic P., Ika-Sari C., Walton A.S., Krum H., Sobotka P.A., Mahfoud F., Bohm M., Lambert G.W., Esler M.D., Schlaich M.P., Renal nerve ablation reduces augmentation index in patients with resistant hypertension. J Hypertens, 2013, 31, 1893–1900. [CrossRef] [PubMed] [Google Scholar]
  • Heusser K., Tank J., Engeli S., Diedrich A., Menne J., Eckert S., Peters T., Sweep F.C., Haller H., Pichlmaier A.M., Luft F.C., Jordan J., Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension, 2010, 55, 619–626. [CrossRef] [PubMed] [Google Scholar]
  • Hoppe U.C., Brandt M.C., Wachter R., Beige J., Rump L.C., Kroon A.A., Cates A.W., Lovett E.G., Haller H., Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens, 2012, 6, 270–276. [CrossRef] [PubMed] [Google Scholar]
  • Kaltenbach B., Id D., Franke J.C., Sievert H., Hennersdorf M., Maier J., Bertog S.C., Renal artery stenosis after renal sympathetic denervation. J Am Coll Cardiol., 2012, 60, 2694–2695. [CrossRef] [PubMed] [Google Scholar]
  • Krum H., Schlaich M., Whitbourn R., Sobotka P.A., Sadowski J., Bartus K., Kapelak B., Walton A., Sievert H., Thambar S., Abraham W.T., Esler M., Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet, 2009, 373, 1275–1281. [CrossRef] [PubMed] [Google Scholar]
  • Krum H., Schlaich M.P., Bohm M., Mahfoud F., Rocha-Singh K., Katholi R., Esler M.D., Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet, 2014, 383, 622–629. [CrossRef] [PubMed] [Google Scholar]
  • Mahfoud F., Luscher T.F., Andersson B., Baumgartner I., Cifkova R., Dimario C., Doevendans P., Fagard R., Fajadet J., Komajda M., Lefevre T., Lotan C., Sievert H., Volpe M., Widimsky P., Wijns W., Williams B., Windecker S., Witkowski A., Zeller T., Bohm M., Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J, 2013a, 34, 2149–2157. [CrossRef] [PubMed] [Google Scholar]
  • Mahfoud F., Ukena C., Schmieder R.E., Cremers B., Rump L.C., Vonend O., Weil J., Schmidt M., Hoppe U.C., Zeller T., Bauer A., Ott C., Blessing E., Sobotka P.A., Krum H., Schlaich M., Esler M., Bohm M., Ambulatory Blood Pressure Changes after Renal Sympathetic Denervation in Patients with Resistant Hypertension. Circulation, 2013b, 128, 132–140. [CrossRef] [PubMed] [Google Scholar]
  • Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., Christiaens T., Cifkova R., De Backer G., Dominiczak A., Galderisi M., Grobbee D.E., Jaarsma T., Kirchhof P., Kjeldsen S.E., Laurent S., Manolis A.J., Nilsson P.M., Ruilope L.M., Schmieder R.E., Sirnes P.A., Sleight P., Viigimaa M., Waeber B., Zannad F., Burnier M., Ambrosioni E., Caufield M., Coca A., Olsen M.H., Tsioufis C., van de Borne P., Zamorano J.L., Achenbach S., Baumgartner H., Bax J.J., Bueno H., Dean V., Deaton C., Erol C., Ferrari R., Hasdai D., Hoes A.W., Knuuti J., Kolh P., Lancellotti P., Linhart A., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Tamargo J.L., Tendera M., Torbicki A., Wijns W., Windecker S., Clément D.L., Gillebert T.C., Rosei E.A., Anker S.D., Bauersachs J., Hitij J.B., Caulfield M., De Buyzere M., De Geest S., Derumeaux G.A., Erdine S., Farsang C., Funck-Brentano C., Gerc V., Germano G., Gielen S., Haller H., Jordan J., Kahan T., Komajda M., Lovic D., Mahrholdt H., Ostergren J., Parati G., Perk J., Polonia J., Popescu B.A., Reiner Z., Ryden L., Sirenko Y., Stanton A., Struijker-Boudier H., Vlachopoulos C., Volpe M., Wood D.A., 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 2013, 34, 2159–2219. [CrossRef] [PubMed] [Google Scholar]
  • Myat A., Redwood S.R., Qureshi A.C., Thackray S., Cleland J.G., Bhatt D.L., Williams B., Gersh B.J., Renal sympathetic denervation therapy for resistant hypertension: a contemporary synopsis and future implications. Circ Cardiovasc Interv, 2013, 6, 184–197. [CrossRef] [PubMed] [Google Scholar]
  • Pathak A., Girerd X., Azizi M., Benamer H., Halimi J.M., Lantèlme P., Lefèvre T., Sapoval M., Expert consensus: Renal denervation for the treatment of hypertension. Diagn Interv Imaging, 2012, 93, 386–394. [CrossRef] [PubMed] [Google Scholar]
  • Peet M.M., Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy. Am J Surg, 1948, 75, 48–68. [CrossRef] [PubMed] [Google Scholar]
  • Persell S.D., Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension, 2011, 57, 1076–1080. [CrossRef] [PubMed] [Google Scholar]
  • Persu A., Renkin J., Thijs L., Staessen J.A., Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension, 2012, 60, 596–606. [CrossRef] [PubMed] [Google Scholar]
  • Sarafidis P.A., Bakris G.L., Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol, 2008, 52, 1749–1757. [CrossRef] [PubMed] [Google Scholar]
  • Savard S., Frank M., Bobrie G., Plouin P.F., Sapoval M., Azizi M., Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients. J Am Coll Cardiol, 2012, 60, 2422–2424. [CrossRef] [PubMed] [Google Scholar]
  • Scheffers I.J., Kroon A.A., Schmidli J., Jordan J., Tordoir J.J., Mohaupt M.G., Luft F.C., Haller H., Menne J., Engeli S., Ceral J., Eckert S., Erglis A., Narkiewicz K., Philipp T., de Leeuw P.W., Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol, 2010, 56, 1254–1258. [CrossRef] [PubMed] [Google Scholar]
  • Schlaich M.P., Sobotka P.A., Krum H., Whitbourn R., Walton A., Esler M.D., Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension, 2009, 54, 1195–1201. [CrossRef] [PubMed] [Google Scholar]
  • Schmieder R.E., Redon J., Grassi G., Kjeldsen S.E., Mancia G., Narkiewicz K., Parati G., Ruilope L., van de Borne P., Tsioufis C., ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens, 2012, 30, 837–841. [CrossRef] [PubMed] [Google Scholar]
  • Smithwick R.H., Thompson J.E., Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc, 1953, 152, 1501–1504. [CrossRef] [PubMed] [Google Scholar]
  • Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension, 2011, 57, 911–917. [Google Scholar]
  • Verloop W.L., Vink E.E., Voskuil M., Vonken E.J., Rookmaaker M.B., Bots M.L., Doevendans P.A., Blankestijn P.J., Spiering W., Eligibility for percutaneous renal denervation: the importance of a systematic screening. J Hypertens, 2013, 31, 1662–1668. [CrossRef] [PubMed] [Google Scholar]
  • Vonend O., Antoch G., Rump L.C., Blondin D., Secondary rise in blood pressure after renal denervation. Lancet, 2012, 380, 778. [CrossRef] [PubMed] [Google Scholar]
  • Wustmann K., Kucera J.P., Scheffers I., Mohaupt M., Kroon A.A., de Leeuw P.W., Schmidli J., Allemann Y., Delacretaz E., Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension, 2009, 54, 530–536. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.